News

11-fold increase in sales revenue compared to the same period last year 42.6% increase in the number of CTG tests performed on Pregnabit Pro devices compared to the same period last year Signed a distribution agreement and obtained a certificate issued by the Israeli Ministry of Health, allowing the platform to be sold on the Israeli market Consistently pursuing FDA certification – conducted tests for electromagnetic compliance, as well as tests for compliance with other points of the relevant standards, some of which have already been successfully completed This is a brief summary of what we did in the first quarter of 2023.

We are proud to support knowledge sharing and learning in the healthcare industry. As part of our commitment to advancing healthcare, we were honored to be a partner of the IV Oncology Weekend at WUM, where leading experts shared their knowledge and experiences in the field of oncology. We are happy to be part of such an important initiative and look forward to supporting future events like this.

Israel – it is the next country where women will have access to a mobile CTG – the Pregnabit Pro and Pregnabit Cloud platform. Nestmedic has signed a distribution agreement with Medlife LTD, which will provide sales and marketing in the Israeli market. The Israeli healthcare system has been recognized as the one of the most effective for years, and telemedicine solutions have been well-known and used. And what is important, Pregnabit Pro is the only registered mobile CTG device on the market there!